ARCH, one of life sci­ences' pre­mier in­vestors, eyes $3B for 13th fund

ARCH Ven­ture Part­ners plans to raise $3 bil­lion for its 13th fund, per a new SEC fil­ing from this week.

The Chica­go-based ven­ture cap­i­tal firm has been one of the most high-pro­file back­ers of life sci­ences com­pa­nies for the past few decades and is be­hind many big names like Il­lu­mi­na, Al­tos Labs and Vir Biotech­nol­o­gy, among dozens of oth­ers.

The firm was the fourth most ac­tive in­vestor in pri­vate fi­nanc­ings last year, per a re­cent re­port from in­vest­ment bank William Blair, hav­ing tak­en part in 18 rounds in 2023. Or­biMed, which un­veiled $4.3 bil­lion across three new funds last fall, took first with 24 rounds. Flag­ship Pi­o­neer­ing, the in­vestor and biotech cre­ator be­hind the likes of Mod­er­na, is al­so seek­ing $3 bil­lion for its next fund, per an SEC fil­ing last No­vem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER